Email Alert RSS
Volume 13 Issue 4
Jul.  2022
Turn off MathJax
Article Contents
Abstract
References
Related Articles
WANG Xixi, WAN Xinhua. Clinical Diagnosis and Treatment of Tardive Dyskinesia[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 644-651. DOI: 10.12290/xhyxzz.2021-0717
Citation: WANG Xixi, WAN Xinhua. Clinical Diagnosis and Treatment of Tardive Dyskinesia[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 644-651. DOI: 10.12290/xhyxzz.2021-0717
shu

Clinical Diagnosis and Treatment of Tardive Dyskinesia

  • Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

National Natural Science Foundation of China 81971074

More Information
  • Corresponding author:

    WAN Xinhua, E-mail: wxhpumch@163.com

  • Received Date: October 28, 2021
  • Accepted Date: November 21, 2021
  • Available Online: January 29, 2022
  • Issue Publish Date: July 29, 2022
    Graphical Abstract
    • Abstract
  • Tardive dyskinesia(TD) is a kind of disabling movement disorder characterized by involuntary movements of the face, neck, extremities or trunk that results from long-term use of dopamine receptor blocking agents.The most common reason is the use of antipsychotic drug(APD). Identified risk factors include the type, dose, as well as the duration of APD. Age, sex, genetics also play a role. CYP2D6, DRD2, DRD3, HTR2A, HTR2C, VMAT2, MnSOD, HSPG2 gene may be involved. The pathogenesis is not clear. Three hypotheses are proposed: dopamine receptor super-sensitivity, oxidative stress and maladaptive synaptic plasticity. TD is quite hard to cure, prevention is of vital importance. This article reviews the clinical diagnosis and treatment of TD, so as to further deepen medical staff's understanding of TD.
    • FullText(HTML)
    • References (60)
  • [1]
    Zutshi D, Cloud LJ, Factor SA. Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic[J]. Tremor Other Hyperkinet Mov(N Y), 2014, 4: 266. DOI: 10.5334/tohm.199
    [2]
    Carbon M, Hsieh CH, Kane JM, et al. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis[J]. J Clin Psychiatry, 2017, 78: e264-e278. DOI: 10.4088/JCP.16r10832
    [3]
    Schonecker M. Paroxysmal dyskinesia as the effect of megaphen[J]. Nervenarzt, 1957, 28: 550-553. https://www.ncbi.nlm.nih.gov/pubmed/12583484
    [4]
    Vinuela A, Kang UJ. Reversibility of tardive dyskinesia syndrome[J]. Tremor Other Hyperkinet Mov (N Y), 2014, 4: 282. DOI: 10.5334/tohm.217
    [5]
    Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications[J]. J Clin Psychiatry, 1993, 54: 133-139.
    [6]
    Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients[J]. Arch Gen Psychiatry, 1995, 52: 756-765. DOI: 10.1001/archpsyc.1995.03950210050010
    [7]
    Patel RS, Mansuri Z, Chopra A. Analysis of risk factors and outcomes in psychiatric inpatients with tardive dyskinesia: A nationwide case-control study[J]. Heliyon, 2019, 5: e01745. DOI: 10.1016/j.heliyon.2019.e01745
    [8]
    Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis[J]. BMC Neurol, 2019, 19: 174. DOI: 10.1186/s12883-019-1385-4
    [9]
    Saklad SR. Identifying Tardive Dyskinesia: Risk Factors, Functional Impact, and Diagnostic Tools[J]. J Clin Psychiatry, 2020, 81: TV18059BR1C.
    [10]
    Uludag K, Wang DM, Goodman C, et al. Prevalence, clinical correlates and risk factors associated with Tardive Dyskinesia in Chinese patients with schizophrenia[J]. Asian J Psychiatr, 2021, 66: 102877. DOI: 10.1016/j.ajp.2021.102877
    [11]
    van Harten PN, Tenback DE. Tardive dyskinesia: clinical presentation and treatment[J]. Int Rev Neurobiol, 2011, 98: 187-210. https://www.sciencedirect.com/science/article/pii/B9780123813282000080
    [12]
    Meltzer HY. Update on typical and atypical antipsychotic drugs[J]. Annu Rev Med, 2013, 64: 393-406. DOI: 10.1146/annurev-med-050911-161504
    [13]
    Blanchet PJ. A Focused Update on Tardive Dyskinesia[J]. Can J Neurol Sci, 2020, 47: 747-755. DOI: 10.1017/cjn.2020.131
    [14]
    Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia[J]. Aliment Pharmacol Ther, 2010, 31: 11-9. DOI: 10.1111/j.1365-2036.2009.04189.x
    [15]
    Alford EL, Wheless JW, Phelps SJ. Treatment of Genera-lized Convulsive Status Epilepticus in Pediatric Patients[J]. J Pediatr Pharmacol Ther, 2015, 20: 260-289. DOI: 10.1385/1-59259-945-1:265
    [16]
    Cornett EM, Novitch M, Kaye AD, et al. Medication-Induced Tardive Dyskinesia: A Review and Update[J]. Ochsner J, 2017, 17: 162-174. https://www.ncbi.nlm.nih.gov/pubmed/6106395
    [17]
    Caroff SN. Recent Advances in the Pharmacology of Tardive Dyskinesia[J]. Clin Psychopharmacol Neurosci, 2020, 18: 493-506. DOI: 10.9758/cpn.2020.18.4.493
    [18]
    Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis[J]. Mov Disord, 2012, 27: 1205-1215.
    [19]
    Seeman P, Tinazzi M. Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2013, 44: 178-183. DOI: 10.1016/j.pnpbp.2013.02.011
    [20]
    Frei K. Tardive dyskinesia: Who gets it and why[J]. Parkinsonism Relat Disord, 2019, 59: 151-154. DOI: 10.1016/j.parkreldis.2018.11.017
    [21]
    Zai CC, Maes MS, Tiwari AK, et al. Genetics of tardive dyskinesia: Promising leads and ways forward[J]. J Neurol Sci, 2018, 389: 28-34. DOI: 10.1016/j.jns.2018.02.011
    [22]
    Koola MM, Tsapakis EM, Wright P, et al. Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?[J]. J Psychopharmacol, 2014, 28: 665-670. DOI: 10.1177/0269881114523861
    [23]
    Lu JY, Tiwari AK, Freeman N, et al. Liver enzyme CYP2D6 gene and tardive dyskinesia[J]. Pharmacogenomics, 2020, 21: 1065-1072. DOI: 10.2217/pgs-2020-0065
    [24]
    Vaiman EE, Shnayder NA, Novitsky MA, et al. Candidate Genes Encoding Dopamine Receptors as Predictors of the Risk of Antipsychotic-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenic Patients[J]. Biomedicines, 2021, 9: 879 DOI: 10.3390/biomedicines9080879
    [25]
    Tsai HT, Caroff SN, Miller DD, et al. A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial[J]. Am J Med Genet B Neuropsychiatr Genet, 2010, 153B: 336-340. https://pubmed.ncbi.nlm.nih.gov/19475583/
    [26]
    Zai CC, Tiwari AK, Mazzoco M, et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia[J]. J Psychiatr Res, 2013, 47: 1760-1765. DOI: 10.1016/j.jpsychires.2013.07.025
    [27]
    Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility[J]. Psychopharmacology(Berl), 2000, 152: 408-413. DOI: 10.1007/s002130000521
    [28]
    Syu A, Ishiguro H, Inada T, et al. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia[J]. Neuropsychopharmacology, 2010, 35: 1155-1164. DOI: 10.1038/npp.2009.220
    [29]
    Greenbaum L, Alkelai A, Zozulinsky P, et al. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations[J]. Pharmacogenomics J, 2012, 12: 513-520. DOI: 10.1038/tpj.2011.32
    [30]
    Zai CC, Lee FH, Tiwari AK, et al. Investigation of the HSPG2 Gene in Tardive Dyskinesia-New Data and Meta-Analysis[J]. Front Pharmacol, 2018, 9: 974. DOI: 10.3389/fphar.2018.00974
    [31]
    Arinami T, Inada T. Genome-wide association analyses for neuroleptic-induced tardive dyskinesia[J]. Nihon Shinkei Seishin Yakurigaku Zasshi, 2011, 31: 155-162.
    [32]
    Aberg K, Adkins DE, Bukszár J, et al. Genomewide association study of movement-related adverse antipsychotic effects[J]. Biol Psychiatry, 2010, 67: 279-282. DOI: 10.1016/j.biopsych.2009.08.036
    [33]
    Inada T, Koga M, Ishiguro H, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia[J]. Pharmacogenet Genomics, 2008, 18: 317-323. DOI: 10.1097/FPC.0b013e3282f70492
    [34]
    Levchenko A, Kanapin A, Samsonova A, et al. A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2021, 105: 110134. DOI: 10.1016/j.pnpbp.2020.110134
    [35]
    Ayhan F, Konopka G. Regulatory genes and pathways disrupted in autism spectrum disorders[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2019, 89: 57-64. https://www.sciencedirect.com/science/article/pii/S0278584618304615
    [36]
    Li W, Pozzo-Miller L. Dysfunction of the corticostriatal pathway in autism spectrum disorders[J]. J Neurosci Res, 2020, 98: 2130-2147. DOI: 10.1002/jnr.24560
    [37]
    Lam M, Chen CY, Li Z, et al. Comparative genetic architectures of schizophrenia in East Asian and European populations[J]. Nat Genet, 2019, 51: 1670-1678. https://www.biorxiv.org/content/biorxiv/early/2018/10/18/445874.full.pdf
    [38]
    Lam M, Hill WD, Trampush JW, et al. Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways[J]. Am J Hum Genet, 2019, 105: 334-350. https://www.academia.edu/en/58176685/Pleiotropic_Meta_Analysis_of_Cognition_Education_and_Schizophrenia_Differentiates_Roles_of_Early_Neurodevelopmental_and_Adult_Synaptic_Pathways
    [39]
    Sollis E, Graham SA, Vino A, et al. Identification and functional characterization of de novo FOXP1 variants provides novel insights into the etiology of neurodevelopmental disorder[J]. Hum Mol Genet, 2016, 25: 546-557. https://academic.oup.com/hmg/article/25/3/546/2384672
    [40]
    Lim K, Lam M, Zai C, et al. Genome wide study of tardive dyskinesia in schizophrenia[J]. Transl Psychiatry, 2021, 11: 351.
    [41]
    Caroff SN, Leong SH, Roberts CB, et al. Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia[J]. J Clin Psychopharmacol, 2020, 40: 373-380.
    [42]
    Jain R, Correll CU. Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis[J]. J Clin Psychiatry, 2018, 79: nu17034ah1c. https://ohsu.pure.elsevier.com/en/publications/the-differential-diagnosis-of-tardive-dyskinesia-2
    [43]
    Solmi M, Pigato G, Kane JM, et al. Clinical risk factors for the development of tardive dyskinesia[J]. J Neurol Sci, 2018, 389: 21-27. https://www.sciencedirect.com/science/article/pii/S0022510X18300704
    [44]
    Erbe S. Prevention and Treatment of Antipsychotic-induced Tardive Dyskinesia[J]. Fortschr Neurol Psychiatr, 2019, 87: 217-224.
    [45]
    Caroff SN, Citrome L, Meyer J, et al. A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia[J]. J Clin Psychiatry, 2020, 81: 19cs12983.
    [46]
    Khorassani F, Luther K, Talreja O. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia[J]. Am J Health Syst Pharm, 2020, 77: 167-174.
    [47]
    Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment Recommendations for Tardive Dyskinesia[J]. Can J Psychiatry, 2019, 64: 388-399. https://europepmc.org/article/pmc/6591749
    [48]
    Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia[J]. Am J Psychiatry, 2020, 177: 868-872.
    [49]
    Margolius A, Fernandez HH. Current treatment of tardive dyskinesia[J]. Parkinsonism Relat Disord, 2019, 59: 155-160. https://www.sciencedirect.com/science/article/pii/S135380201830556X
    [50]
    Arya D, Khan T, Margolius AJ, et al. Tardive Dyskinesia: Treatment Update[J]. Curr Neurol Neurosci Rep, 2019, 19: 69. https://www.ncbi.nlm.nih.gov/pubmed/6106395
    [51]
    Lindenmayer JP, Verghese C, Marder SR, et al. A long-term, open-label study of valbenazine for tardive dyskinesia[J]. CNS Spectr, 2021, 26: 345-353.
    [52]
    Debrey SM, Goldsmith DR. Tardive Dyskinesia: Spotlight on Current Approaches to Treatment[J]. Focus (Am Psychiatr Publ), 2021, 19: 14-23.
    [53]
    Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy[J]. Am J Psychiatry, 1990, 147: 445-451. https://www.ncbi.nlm.nih.gov/pubmed/6241738
    [54]
    Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia[J]. J Clin Psychopharmacol, 1997, 17: 88-91.
    [55]
    Pappa S, Tsouli S, Apostolou G, et al. Effects of amantad-ine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study[J]. Clin Neuropharmacol, 2010, 33: 271-275.
    [56]
    Zhang WF, Tan YL, Zhang XY, et al. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial[J]. J Clin Psychiatry, 2011, 72: 615-621.
    [57]
    Pouclet-Courtemanche H, Rouaud T, Thobois S, et al. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia[J]. Neurology, 2016, 86: 651-659. https://www.ncbi.nlm.nih.gov/pubmed/26791148
    [58]
    Gruber D, Südmeyer M, Deuschl G, et al. Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trial[J]. Brain Stimul, 2018, 11: 1368-1377. https://www.sciencedirect.com/science/article/pii/S1935861X18302894
    [59]
    Factor SA. Management of Tardive Syndrome: Medications and Surgical Treatments[J]. Neurotherapeutics, 2020, 17: 1694-1712.
    [60]
    Chen CY, Chiang HL, Fuh JL. Tardive syndrome: An update and mini-review from the perspective of phenomeno-logy[J]. J Chin Med Assoc, 2020, 83: 1059-1065.
    • Related Articles

  • Related Articles

    [1]ZHOU Yongtai, YANG Zhenyu, LI Yan, WU Jiajing, ZHAO Bo. Research Progress on the Mechanism of Lipocalin-2 in Neurological Diseases[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2025-0028
    [2]WEI Jiaojiao, LIU Shiwei, DUAN Ruixue, LI Nan, WANG Jiangna. Effects of Vaspin on Pancreatic Beta Cell Function in Type 2 Diabetic Rats by AMPK/mTOR Autophagy Signaling Pathway[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 543-552. DOI: 10.12290/xhyxzz.2022-0183
    [3]LI Yi, XU Yingchun. A New Chapter in the COVID-19 Pandemic: the Characteristics of Omicron Variant and A New Step for Scientific Epidemic Prevention and Control[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 9-17. DOI: 10.12290/xhyxzz.2022-0697
    [4]LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271
    [5]ZHAO Zhe, TANG Yan, ZHOU Jingya, CHEN Xiaoguang, ZHANG Lei, CHEN Limeng, YUAN Tao. Analysis of Clinical Manifestations and Drug Therapies of Gitelman Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 277-286. DOI: 10.12290/xhyxzz.2021-0180
    [6]Huai-ya XIE, Chao LI, Yu-bing WEN, Wei YE, Jian-fang CAI, Hang LI, Xue-mei LI, Xue-wang LI. Efficacy and Prognosis of Calcineurin inhibitors and Cyclophosphamide in Treating Idiopathic Membranous Nephropathy in Patients with Type 2 Diabetes[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 296-300. DOI: 10.3969/j.issn.1674-9081.20180463
    [7]Jia-qi ZHANG, Lei LIU, Gui-ge WANG, Wen-liang BAI, Shan-qing LI. Clinical Pathological Features and Prognosis of Non-small Cell Lung Cancer with Skip N2 Lymph Node Metastasis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 272-277. DOI: 10.3969/j.issn.1674-9081.2019.03.015
    [9]Xiao-hua SHI, Zhi-yong LIANG, Huan-wen WU, Xin-yu REN, Tong-hua LIU. Effect of RNA Interference Plasmid on the Expression of Oncogene AKT2 in Pancreatic Cancer Cell Line Panc-1[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(1): 102-108. DOI: 10.3969/j.issn.1674-9081.2012.01.021
    [10]Xin-yu REN, Yu-feng YIN, Jie GAO, Sha-fei WU, Ke WANG, Wen-ze WANG, Xuan ZENG, Zhi-yong LIANG. Detection of HER2/neu Gene in Pancreatic and Gastric Adenocarcinoma among Chinese Patients[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(1): 21-25. DOI: 10.3969/j.issn.1674-9081.2012.01.006

  • Cited by

    Periodical cited type(7)

    1. 刘梦薇，曾聪，王与嫣，陈益丹. “十三鬼穴”结合微针刀治疗迟发性运动障碍一例. 浙江中西医结合杂志. 2024(06): 558-559 .
    2. 刘亚丽，李克松，靳红强，崔月，王小方，刘雅，高玉，陈运昭. 重复经颅磁刺激对精神分裂症患者迟发性运动障碍的干预效果. 实用临床医药杂志. 2024(13): 98-102+108 .
    3. 赵恺，陈燕娣，李晓一. 小剂量喹硫平所致迟发性运动障碍1例. 浙江医学. 2023(03): 313-314 .
    4. 司天梅，李茜. 注射用利培酮微球临床应用专家共识. 中国心理卫生杂志. 2023(08): 641-647 .
    5. 阮召锐，何舒萍，林美金. 不同病程的迟发性运动障碍的治疗效果. 名医. 2023(07): 54-56 .
    6. 莫翠莲，罗树明，陈春梅. 207例精神分裂症伴迟发性运动障碍患者社会功能现状及影响因素分析. 实用预防医学. 2023(09): 1127-1130 .
    7. 翟晓艳，吕晓珍，倪爱华，刘粹. 住院患者第2代抗精神病药治疗相关迟发性运动障碍的危险因素. 临床精神医学杂志. 2023(06): 430-434 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (807) PDF downloads (228) Cited by(8)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close